Status:
RECRUITING
Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting
Lead Sponsor:
AbbVie
Conditions:
Chronic Lymphocytic Leukemia (CLL)
Eligibility:
All Genders
18+ years
Brief Summary
An observational study to assess the effectiveness, health economic-relevant costs and participant reported outcomes in participants with Chronic lymphocytic leukemia (CLL) receiving venetoclax as a m...
Eligibility Criteria
Inclusion
- \- Participant with chronic lymphocytic leukemia (CLL) who start venetoclax therapy can be included in the study if treated as specified in the local label for any specific line of treatment.
Exclusion
- \- None
Key Trial Info
Start Date :
December 4 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2030
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT03342144
Start Date
December 4 2017
End Date
December 1 2030
Last Update
December 8 2025
Active Locations (70)
Enter a location and click search to find clinical trials sorted by distance.
1
Universitaetsklinikum St. Poelten /ID# 221152
Sankt Pölten, Lower Austria, Austria, 3100
2
Medizinische Universitaet Graz /ID# 221155
Graz, Styria, Austria, 8010
3
Landeskrankenhaus Salzburg-Universitaetsklinikum der PMU (LKH) /ID# 221153
Salzburg, Austria, 5020
4
Hanusch Krankenhaus /ID# 221151
Vienna, Austria, 1140